BiomX Presenting at Three Upcoming Investor Conferences

Rhea-AI Summary

BiomX (NYSE American: PHGE) has announced that CEO Jonathan Solomon will present at three notable conferences in 2022. These include the Aegis Virtual Conference on February 24, the Chardan 4th Annual Microbiome Medicines Summit on March 1, and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17. The presentations will highlight the company's development of innovative phage therapies targeting pathogenic bacteria related to various chronic diseases. Live webcasts will be available on BiomX's website.

2022 Aegis Virtual Conference on February 24, 2022

Chardan 4^th Annual Microbiome Medicines Summit on March 1, 2022

Oppenheimer & Co. 32^nd Annual Virtual Healthcare Conference on March 17, 2022

NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4^th Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co. 32^nd Annual Healthcare Conference on March 17, 2022.

2022 Aegis Virtual Conference – February 23-25, 2022
Date & Time:		Thursday, March 24, 2:30 PM EST
Presenter:		Jonathan Solomon
Conference registration:		Link
Chardan 4th Annual Microbiome Medicines Summit – March 1, 2022
Date & Time:		Tuesday, March 1, 8:30 AM EST
Presenter: Conference registration:		Jonathon Solomon Link
Oppenheimer & Co. 32nd Annual Healthcare Conference – March 15-17, 2022
Date & Time:		Thursday, March 17, 2:00 PM EST
Presenter:		Jonathan Solomon
Conference registration:		Link

Live webcasts of presentations will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.

About BiomX Inc.

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005117/en/

BiomX Contacts



Investor Relations:

LifeSci Advisors, LLC

John Mullaly

(617)-698-9253

jmullaly@lifesciadvisors.com



BiomX, Inc.

Anat Primovich

Corporate Project Manager

+972 (50) 697-7228

anatp@biomx.com

Source: BiomX Inc.

FAQ

When will Jonathan Solomon present at the Aegis Virtual Conference?

Jonathan Solomon will present at the Aegis Virtual Conference on February 24, 2022.

What are the dates for the Chardan 4th Annual Microbiome Medicines Summit?

The Chardan 4th Annual Microbiome Medicines Summit will take place on March 1, 2022.

What is the focus of the presentations by BiomX at these conferences?

BiomX's presentations will focus on their novel phage therapies targeting pathogenic bacteria linked to chronic diseases.

Where can I watch the live webcasts of BiomX's conference presentations?

Live webcasts of BiomX's presentations will be available in the Investors section of their website.

What is the significance of BiomX's participation in these conferences?

BiomX's participation highlights their innovative research in microbiome therapies and potential treatments for chronic diseases.